Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to “Hold” at Wall Street Zen

Posted by Stanley Muller on May 17th, 2026

Wall Street Zen upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on the company. Cantor Fitzgerald boosted their price objective on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Weiss Ratings downgraded Rocket Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Lifesci Capital upgraded Rocket Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 26th. Chardan Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Rocket Pharmaceuticals in a report on Monday, May 11th. Finally, Bank of America boosted their price objective on Rocket Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Rocket Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $11.54.

View Our Latest Report on RCKT

Rocket Pharmaceuticals Price Performance

RCKT stock opened at $3.25 on Friday. The business has a fifty day moving average of $3.94 and a two-hundred day moving average of $3.67. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.08. The stock has a market cap of $354.87 million, a price-to-earnings ratio of -1.74 and a beta of 0.52. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $6.89.

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.01). During the same period in the prior year, the business earned ($0.56) earnings per share. As a group, research analysts anticipate that Rocket Pharmaceuticals will post -1.24 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Sarbani Chaudhuri sold 17,650 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $3.84, for a total transaction of $67,776.00. Following the completion of the transaction, the insider directly owned 267,510 shares of the company’s stock, valued at $1,027,238.40. The trade was a 6.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 25,751 shares of company stock worth $96,708. Insiders own 21.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RCKT. Monaco Asset Management SAM grew its stake in Rocket Pharmaceuticals by 538.8% during the 3rd quarter. Monaco Asset Management SAM now owns 2,892,261 shares of the biotechnology company’s stock worth $9,429,000 after purchasing an additional 2,439,494 shares in the last quarter. MPM Bioimpact LLC grew its stake in Rocket Pharmaceuticals by 141.2% during the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock worth $9,563,000 after purchasing an additional 2,284,816 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in Rocket Pharmaceuticals by 690.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,548,262 shares of the biotechnology company’s stock worth $3,793,000 after purchasing an additional 1,352,469 shares in the last quarter. Millennium Management LLC grew its stake in Rocket Pharmaceuticals by 52.0% during the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock worth $11,639,000 after purchasing an additional 1,221,554 shares in the last quarter. Finally, Maverick Capital Ltd. grew its stake in Rocket Pharmaceuticals by 42.0% during the 1st quarter. Maverick Capital Ltd. now owns 3,567,372 shares of the biotechnology company’s stock worth $12,771,000 after purchasing an additional 1,054,262 shares in the last quarter. 98.39% of the stock is owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Company Profile

(Get Free Report)

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.